Alopecia areata following pembrolizumab: A case report and literature review. Issue 4 (13th April 2022)

• Record Type: Journal Article
• Authors: Hara, Reiko; Sawada, Yu
• Is Part Of: Journal of cutaneous immunology and allergy. Volume 5:Issue 4(2022)
• Page Start: 153
• Page End: 154
• Publication Date: 2022-04-13
• Subjects: Skin -- Diseases -- Immunological aspects -- Periodicals; Skin -- Diseases -- Periodicals; Skin -- Diseases -- Treatment -- Periodicals; 616.5079
• DOI: 10.1002/cia2.12236
• Languages: English
• ISSNs: 2574-4593

Abstract

Abstract : Since malignancies develop their escape strategy from anti‐tumor immunity mediated by PD‐1/PD‐L1 or CTLA‐4, the recent advancement of immune checkpoint inhibitor treatment proves the importance of immune reaction against malignancies. On the other hand, healthy human tissue or organs also need to tolerance mechanism escaping from immune reactions not to cause excessive inflammatory reactions. We report a case of alopecia areata following pembrolizumab administration and also review the previously published cases of alopecia areata following PD‐1/PD‐L1 targeted therapy further.